Parathyroid hormone

(Natpara®)

Natpara®

Drug updated on 5/22/2024

Dosage FormInjection (subcutaneous; 25 mcg, 50 mcg, 75 mcg, 100 mcg)
Drug ClassParathyroid hormones
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Parathyroid hormone (Natpara) is used alongside calcium and vitamin D to manage hypocalcemia in individuals with hypoparathyroidism. It seeks to imitate the actions of natural PTH, demonstrating similar efficacy to standard treatments but potentially offering safer outcomes for long-term kidney health due to decreased urinary calcium excretion.
  • The analysis is based on seven systematic reviews and meta-analyses examining the safety, efficacy, and specificities of Natpara treatment in comparison to standard therapies, such as calcium and/or vitamin D supplementation.
  • In the case of postoperative hypoparathyroidism following total thyroidectomy, immediate supplementation has no significant impact on the long-term recovery of parathyroid function. This signifies that although PTH replacement was not directly examined, conventional supplementation effectively averts acute complications without affecting the success or safety of chronic management.
  • Continuous pump infusion of PTH has led to quick improvement in clinical parameters without severe side effects for individuals with chronic hypoparathyroidism not managed by standard treatments. This suggests a favorable safety profile especially for those unresponsive to oral supplementation regimes.
  • Early determination of serum PTH after thyroidectomy can foresee the onset of chronic hypoparathyroidism, underlining its critical role in management without directly comparing the effectiveness of therapies such as Natpara.
  • Parathyroid Allotransplant (PA), an alternative method for treating permanent hypoparathyroidism, has shown a considerable success rate, particularly in reducing the necessity for pharmacological treatments like Natpara among certain patient groups. However, it necessitates immunosuppression, which restricts its use compared to pharmacological options that do not require such measures.

Product Monograph / Prescribing Information

Document TitleYearSource
Natpara (parathyroid hormone) Prescribing Information.2022Shire-NPS Pharmaceuticals, Inc., Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines